Precision Cardiovascular is creating a cardiac monitoring system for remote management of heart failure (HF). The product consists of an innovative, implantable high accuracy pressure sensor, capable of 24-hour continuous transmission of the heart's response during in-home activity. The system facilitates early physician assessment and tailored intervention. Particularly for patients with preserved ejection fraction (HFpEF), the system potentially improves outcomes for millions of patients and significantly reduces the burden and costs of hospital admissions. The company expects to reach full readiness for first-in-man trials by the end of 2023.